文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

老年或体弱胶质母细胞瘤患者短程放疗成本效果更优

Improved cost-effectiveness of short-course radiotherapy in elderly and/or frail patients with glioblastoma.
PubMed 文献 · Radiother Oncol · 2018-02-13

基于随机III期试验数据,比较老年和/或体弱胶质母细胞瘤患者短程放疗(25 Gy/5次)与40 Gy/15次的成本效果。短程组中位OS 8.2个月对7.7个月(p=0.340),PFS无差异(p=0.686),但RMOS增加0.11生命年,ICER为每获得生命年节省3062美元。

要点

  • 短程放疗与长程放疗中位OS和PFS均无显著差异。
  • 短程放疗ICER为每生命年节省3062美元。
  • 短程放疗每PFS获益节省17693美元。

核心结论

  • 短程放疗(25 Gy/5次)相比40 Gy/15次成本更低,ICER为每获得生命年节省3062美元。

研究设计与样本

  • 基于随机III期试验的成本效果分析,直接成本数据来自5个主要贡献国、覆盖88%的患者。

主要发现

  • 短程组与常用放疗组中位OS分别为8.2个月(95%CI 6.1-10.3)和7.7个月(95%CI 5.5-9.9),log rank p=0.340。
  • 两组中位PFS无差异(p=0.686)。
  • RMOS差异为+0.11生命年,ICER为-3062美元/生命年。
  • RMPFS差异为+0.02 PFS,ICER为-17693美元/PFS。

临床怎么用

  • 在老年和/或体弱胶质母细胞瘤患者中,短程放疗可作为成本更低且疗效非劣的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Short-course radiotherapy (25 Gy in five fractions) was recently shown in a randomized phase III trial to be non-inferior to 40 Gy in 15 fractions in elderly and/or frail patients with glioblastoma multiforme. This study compared the cost-effectiveness of the two regimens. MATERIAL AND METHODS: The direct unit costs of imaging, radiotherapy (RT), and dexamethasone were collected from the five primary contributing countries to the trial, constituting the data of 88% of all patients. Effectiveness was measured by the restricted mean overall survival (RMOS) and progression free survival (RMPFS). The incremental cost-effectiveness ratio (ICER) was calculated. Indirect costs were also estimated for comparison. RESULTS: The median OSs for the short-course and commonly used RTs were 8.2 (95% confidence interval [CI] 6.1-10.3) and 7.7 (95% CI 5.5-9.9) months, respectively (log rank p = 0.340). Median PFSs were also not different (p = 0.686). The differences in the RMOS and the ICER, however, were +0.11 life-years and -$3062 United States dollars (USD) per life-year gained, respectively. The differences in the RMPFS and the ICER were +0.02 PFS and -$17,693 USD, respectively. CONCLUSION: The ICER of -$3062 per life-year gained and -$17,693 per PFS gained indicates that the short-course RT is less costly compared to the longer RT regimen.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Ghosh S, Baker S, de Castro DG, et al. Improved cost-effectiveness of short-course radiotherapy in elderly and/or frail patients with glioblastoma. Radiother Oncol. 2018. PMID: 29452901. doi:10.1016/j.radonc.2018.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。